Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00684242 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00684242: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00684242 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00684242, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if lenalidomide can help to treat uncontrolled pain caused by advanced cancer. Primary Objectives: 1\. Determine efficacy of Lenalidomide for the treatment of refractory cancer pain, as measured by the change on Edmonton symptom assessment scale (ESAS). Secondary Objectives: 1. To determine the effect of Lenalidomide on fatigue, sleep, depressed mood, nausea and appetite/anorexia. 2. Determine changes in serum levels of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha, interferon(IFN)-alpha and IFN-gamma, and C-reactive protein) before and after treatment with Lenalidomide. 3. Effect of Lenalidomide on T-cell subsets especially T-regulatory cells 4. Effect of Lenalidomide on the expression of costimulatory receptors, CD80, CD86, and CD40, on myeloid and plasmacytoid dendritic cells 5. Safety (type, frequency, severity, and relationship of adverse events to study treatment)
Interventions
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-05 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00684242
The ClinicalTrials.gov registry entry for NCT00684242 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.
NCT00684242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00684242 about?
NCT00684242 is a clinical study titled "Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain". The goal of this clinical research study is to learn if lenalidomide can help to treat uncontrolled pain caused by advanced cancer. Primary Objectives: 1\. Determine efficacy of Lenalidomide for the treatment of refractory cancer pain, as measured by the change on Edmonton symptom assessment scale...
What is the current status of trial NCT00684242?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2008-05. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00684242?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00684242?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.